Aldeyra Therapeutics Inc.

3.99+0.1200+3.10%Vol 760.90K1Y Perf -67.53%
Jun 28th, 2022 16:00 DELAYED
BID3.65 ASK4.10
Open3.95 Previous Close3.87
Pre-Market- After-Market3.87
 - -  -0.12 -3.01%
Target Price
16.60 
Analyst Rating
Strong Buy 1.00
Potential %
316.04 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
16.93 
Earnings Rating
Sell
Market Cap232.62M 
Earnings Date
4th Aug 2022
Alpha0.00 Standard Deviation0.24
Beta1.64 

Today's Price Range

3.874.04

52W Range

2.3612.01

5 Year PE Ratio Range

-4.50-3.90

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
21.70%
1 Month
24.84%
3 Months
-25.15%
6 Months
-4.68%
1 Year
-67.53%
3 Years
-35.50%
5 Years
-14.00%
10 Years
-

TickerPriceChg.Chg.%
ALDX3.990.12003.10
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.31-0.296.45
Q04 2021-0.31-0.2712.90
Q03 2021-0.29-0.276.90
Q02 2021-0.27-0.28-3.70
Q01 2021-0.29-0.2513.79
Q04 2020-0.26-0.35-34.62
Q03 2020-0.28-0.2317.86
Q02 2020-0.34-0.2526.47
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.32-3.23Negative
9/2022 QR-0.34-6.25Negative
12/2022 FY-1.37-3.79Negative
12/2023 FY-1.67-20.14Negative
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.32
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume760.90K
Shares Outstanding58.30K
Shares Float47.36M
Trades Count5.76K
Dollar Volume3.00M
Avg. Volume1.49M
Avg. Weekly Volume2.14M
Avg. Monthly Volume1.43M
Avg. Quarterly Volume908.13K

Aldeyra Therapeutics Inc. (NASDAQ: ALDX) stock closed at 3.87 per share at the end of the most recent trading day (a 5.16% change compared to the prior day closing price) with a volume of 1.05M shares and market capitalization of 232.62M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 11 people. Aldeyra Therapeutics Inc. CEO is Todd C. Brady.

The one-year performance of Aldeyra Therapeutics Inc. stock is -67.53%, while year-to-date (YTD) performance is -3.25%. ALDX stock has a five-year performance of -14%. Its 52-week range is between 2.355 and 12.01, which gives ALDX stock a 52-week price range ratio of 16.93%

Aldeyra Therapeutics Inc. currently has a PE ratio of -3.30, a price-to-book (PB) ratio of 1.13, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.98%, a ROC of -35.55% and a ROE of -40.86%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Aldeyra Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.32 for the next earnings report. Aldeyra Therapeutics Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Aldeyra Therapeutics Inc. is Strong Buy (1), with a target price of $16.6, which is +316.04% compared to the current price. The earnings rating for Aldeyra Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aldeyra Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aldeyra Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.30, ATR14 : 0.30, CCI20 : 143.71, Chaikin Money Flow : 0.04, MACD : 0.13, Money Flow Index : 75.23, ROC : 10.57, RSI : 63.17, STOCH (14,3) : 83.16, STOCH RSI : 1.00, UO : 59.01, Williams %R : -16.84), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aldeyra Therapeutics Inc. in the last 12-months were: Martin J. Joyce (Buy at a value of $15 025), Todd C. Brady (Buy at a value of $59 546)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye diseases, allergic conjunctivities, noninfectious anterior uveitis, and Sjogren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal disease, post-transplant lymphoproloferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

CEO: Todd C. Brady

Telephone: +1 781 761-4904

Address: 131 Hartwell Avenue, Lexington 02421, MA, US

Number of employees: 11

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

71%29%

Bearish Bullish

72%28%

Bearish Bullish

61%39%

TipRanks News for ALDX

News

Stocktwits